Abstract
Tuberculosis (TB) and Malaria are neglected diseases, which continue to be major causes of morbidity and mortality worldwide, killing together around 5 million people each year. Mycolic acids, the hallmark of mycobacteria, are high-molecular-weight - alkyl, β-hydroxy fatty acids. Biochemical and genetic experimental data have shown that the product of the M. tuberculosis inhA structural gene (InhA) is the primary target of isoniazid mode of action, the most prescribed anti-tubercular agent. InhA was identified as an NADH-dependent enoyl-ACP(CoA) reductase specific for long-chain enoyl thioesters and is a member of the Type II fatty acid biosynthesis system, which elongates acyl fatty acid precursors of mycolic acids. M. tuberculosis and P. falciparum enoyl reductases are targets for the development of anti-tubercular and antimalarial agents. Here we present a brief description of the mechanism of action of, and resistance to, isoniazid. In addition, data on inhibition of mycobacterial and plasmodial enoyl reductases by triclosan are presented. We also describe recent efforts to develop inhibitors of M. tuberculosis and P. falciparum enoyl reductase enzyme activity.
Keywords: Tuberculosis, mycobacteria, mycolic acids, isoniazid, InhA, enoyl reductase, drugs
Current Drug Targets
Title: Enoyl Reductases as Targets for the Development of Anti-Tubercular and Anti-Malarial Agents
Volume: 8 Issue: 3
Author(s): J. S. Oliveira, I. B. Vasconcelos, I. S. Moreira, D. S. Santos and L. A. Basso
Affiliation:
Keywords: Tuberculosis, mycobacteria, mycolic acids, isoniazid, InhA, enoyl reductase, drugs
Abstract: Tuberculosis (TB) and Malaria are neglected diseases, which continue to be major causes of morbidity and mortality worldwide, killing together around 5 million people each year. Mycolic acids, the hallmark of mycobacteria, are high-molecular-weight - alkyl, β-hydroxy fatty acids. Biochemical and genetic experimental data have shown that the product of the M. tuberculosis inhA structural gene (InhA) is the primary target of isoniazid mode of action, the most prescribed anti-tubercular agent. InhA was identified as an NADH-dependent enoyl-ACP(CoA) reductase specific for long-chain enoyl thioesters and is a member of the Type II fatty acid biosynthesis system, which elongates acyl fatty acid precursors of mycolic acids. M. tuberculosis and P. falciparum enoyl reductases are targets for the development of anti-tubercular and antimalarial agents. Here we present a brief description of the mechanism of action of, and resistance to, isoniazid. In addition, data on inhibition of mycobacterial and plasmodial enoyl reductases by triclosan are presented. We also describe recent efforts to develop inhibitors of M. tuberculosis and P. falciparum enoyl reductase enzyme activity.
Export Options
About this article
Cite this article as:
Oliveira S. J., Vasconcelos B. I., Moreira S. I., Santos S. D. and Basso A. L., Enoyl Reductases as Targets for the Development of Anti-Tubercular and Anti-Malarial Agents, Current Drug Targets 2007; 8 (3) . https://dx.doi.org/10.2174/138945007780058942
DOI https://dx.doi.org/10.2174/138945007780058942 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Evaluation of Antimicrobial Activity of Novel Oxazine Derivatives using Betti’s Protocol
Letters in Drug Design & Discovery Synthesis and Anti-Proliferative Evaluations of New Heterocyclic Derivatives Using 5,6,8,9-Tetrahydropyrazolo[5,1-b]quinazolin-7(3H)-one Derivatives Derived from Cyclohexa-1,4-dione
Anti-Cancer Agents in Medicinal Chemistry Solid Lipid Nanoparticles: A Potential Approach for Drug Delivery System
Nanoscience & Nanotechnology-Asia Vaccine Delivery - Current Trends and Future
Current Drug Delivery Genomic and Genetic Approaches for the Identification of Antifungal Drug Targets
Infectious Disorders - Drug Targets Current Understanding of Dietary Polyphenols and their Role in Health and Disease
Current Nutrition & Food Science Adherence to Antiretroviral Therapy Among Iranian HIV/AIDS Patients
Current Clinical Pharmacology Post-Translational Protein Modifications of Rare and Unconventional Types: Implications in Functions and Diseases
Current Medicinal Chemistry Comparative Proteome Analysis of <i>Mycobacterium Tuberculosis</i> Strains - H37Ra, H37Rv, CCDC5180, and CAS/NITR204: A Step Forward to Identify Novel Drug Targets
Letters in Drug Design & Discovery Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Pneumococcal Infections at Hajj: Current Knowledge Gaps
Infectious Disorders - Drug Targets Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets From the Old Immunitas to the Modern Immunity: Do We Need a New Name for the Immune System?
Current Immunology Reviews (Discontinued) Protein Kinase Homology Models: Recent Developments and Results
Current Medicinal Chemistry Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety?
Current Drug Safety Breath Tests in Diagnosis of Pulmonary Tuberculosis
Recent Patents on Biotechnology Operational Issues and Barriers to Implementation of Prevention of Mother-to-Child Transmission of HIV (PMTCT) Interventions in Sub- Saharan Africa
Current HIV Research Design, Synthesis and Docking Study of Some Novel Isatin- Quinoline Hybrids as Potential Antitubercular Agents
Anti-Infective Agents Mutagenicity of N-oxide Containing Heterocycles and Related Compounds: Experimental and Theoretical Studies
Current Topics in Medicinal Chemistry Pharmacokinetic and Pharmacodynamic Variability: A Daunting Challenge in Drug Therapy
Current Drug Metabolism